Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, Blau IW, Raab MS, Hillengass J, Hose D, Huhn S, Hundemer M, Andrulis M, Jauch A, Seidel-Glaetzer A, Lindemann HW, Hensel M, Fronhoffs S, Martens U, Hansen T, Wattad M, Graeven U, Munder M, Fenk R, Haenel M, Scheid C, Goldschmidt H. Salwender H, et al. Among authors: raab ms. BMC Cancer. 2019 May 28;19(1):504. doi: 10.1186/s12885-019-5600-x. BMC Cancer. 2019. PMID: 31138244 Free PMC article. Clinical Trial.
High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH.
Cremer FW, Kartal M, Hose D, Bila J, Buck I, Bellos F, Raab MS, Brough M, Moebus A, Hager HD, Goldschmidt H, Moos M, Bartram CR, Jauch A. Cremer FW, et al. Among authors: raab ms. Cancer Genet Cytogenet. 2005 Sep;161(2):116-24. doi: 10.1016/j.cancergencyto.2005.02.015. Cancer Genet Cytogenet. 2005. PMID: 16102581
Sorafenib in patients with refractory or recurrent multiple myeloma.
Yordanova A, Hose D, Neben K, Witzens-Harig M, Gütgemann I, Raab MS, Moehler T, Goldschmidt H, Schmidt-Wolf IG. Yordanova A, et al. Among authors: raab ms. Hematol Oncol. 2013 Dec;31(4):197-200. doi: 10.1002/hon.2043. Epub 2013 Mar 15. Hematol Oncol. 2013. PMID: 23494836 Clinical Trial.
Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.
Krämer I, Engelhardt M, Fichtner S, Neuber B, Medenhoff S, Bertsch U, Hillengass J, Raab MS, Hose D, Ho AD, Goldschmidt H, Hundemer M. Krämer I, et al. Among authors: raab ms. Oncoimmunology. 2016 Feb 18;5(5):e1139662. doi: 10.1080/2162402X.2016.1139662. eCollection 2016 May. Oncoimmunology. 2016. PMID: 27467960 Free PMC article.
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.
Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H. Merz M, et al. Among authors: raab ms. Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9. Blood Adv. 2017. PMID: 29344579 Free PMC article. Clinical Trial.
178 results